Anti-fungal composition

a technology of composition and antifungal agent, applied in the field of oral composition, can solve the problems of life-threatening fungal infections, disrupting membranes, and fatal infections, and achieve the effect of enhancing mucosal immunization

Inactive Publication Date: 2011-07-14
IMMUNITOR USA
View PDF1 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Some of such infections especially those that are disseminated are fatal.
The life-threatening fungal infections are a growing problem not only for immunosuppressed or immunocompromised individuals but also in individuals with viral infections, such as cytomegalovirus (CMV), and influenza, for cancer patients receiving chemotherapy or radiotherapy, for transplant patients receiving antirejection agents, and for patients that have received toxic chemicals, metals and radiation exposure.
These are broad-spectrum antifungals that bind to ergosterol, a component of fungal cell membranes, and thereby disrupt the membranes, leading to cell death.
Amphotericin B is usually effective for systemic mycoses, but its administration is limited by toxic effects that include fever and kidney damage, and other accompanying side effects such as anemia, low blood pressure, headache, nausea, vomiting and phlebitis.
Miconazole is a parenteral imidazole with efficacy in coccidioidomycosis and several other mycoses, but has side effects including hyperlipidemia and hyponatremia.
Limitations of current therapeutic options include: inadequate spectrum of activity, lack of efficacy due to growing resistance, poor safety profile, multiple drug interactions, inadequate pharmacokinetic profile, and excessive cost.
Development of antifungal agents is a challenge because there are very few potential drug targets unique to fungi.
Resistance to antifungals has become more apparent in recent years and may worsen with the increase in prophylatic therapy even with new drugs being developed.
However, the number of patents relating to a fungal vaccine is much smaller than those disclosing new antifungal drugs.
Most of vaccine work was done by scientists who were outside of mainstream of fungal drug developers since fungal experts' establishment was not really concerned or convinced by the idea that vaccines would work.
This is mainly due to the deep-rooted conviction that vaccine antigens will degrade in the stomach and thus the activity of the vaccine will be annihilated effectively rendering such a vaccine useless.
However, oral vaccine development is proving lengthy and complex and, at the present time, there is no completely satisfactory antifungal vaccine that is orally available.
The use of antifungal drugs still causes major problems due to widespread drug resistance and the toxicity related effects of present chemotherapy.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0059]One method to produce the antifungal preparation is by dissolving or hydrolyzing the suitable fungi by increasing or reducing the pH using methods known in the art. Preferably the pH is above 10 or below 4. Examples of suitable aqueous acids are aqueous solutions of HCl, H2SO4, citric acid and lactic acid. Examples of suitable alkaline solutions are solutions of hydroxides such as NaOH, KOH and NH4OH. The dissolved fungus can be mixed with the suitable carrier or adjuvant compound, like a protein or amino acid. Preferably a food grade proteins is used. Examples of suitable proteins are milk proteins, e.g. whey proteins, caseins and caseinates or other compounds, such as L-glutamine. Also mixtures of different proteins and mixtures of proteins with other compounds such as fats e.g. vegetable and animal fats or oils such as milk fat, butter fat, soya bean oil and sunflower oil can be used. Also compositions or products which contain mixtures of these compounds can be used. Examp...

example 2

[0061]An effective treatment for arresting the growth of undesired microbes in the preparation comprises pasteurization. Pasteurization generally comprises partial sterilization at a temperature and for a period of time that destroys objectionable organisms, without major chemical alteration of the product. To arrest the activity of the bacteria in the composition of the invention, pasteurization can comprise heating the composition to a temperature of at least about 110 degree F., more preferably at least about 120 degree F., and maintaining that temperature for at least about 30 minutes. According to the so-called “holding method” or “batch pasteurization”, the preparation can be heated to 145 degree F. and held at this temperature for 30 minutes with constant stirring with an agitator at 60 rpm. Alternatively, a high-temperature, short-time process, can be equally employed. This requires a temperature of 162 degree F. for as little as approximately 16 seconds. Even shorter durati...

example 3

[0062]High-pressure commercially available CO2 gas is an ideal solvent. it has the density of a liquid, but is also highly penetrable and diffusible since it has the properties of a gas at the same time.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
pressuresaaaaaaaaaa
pressuresaaaaaaaaaa
pressuresaaaaaaaaaa
Login to view more

Abstract

A multivalent fungal vaccine comprising one or more heat-inactivated fungal antigens, wherein at least one fungal antigen is effective in producing an immune response in a host when said vaccine is administered orally at a dose that is sufficient for preventing or treating the fungal disease in said host. Also described are methods for making and using an orally available anti-fungal vaccine.

Description

FIELD OF THE INVENTION[0001]The invention relates to an oral composition useful for treatment and prevention of fungal diseases. The invention also relates to process of making an orally available antifungal vaccine and methods of use.BACKGROUND OF THE INVENTION[0002]Pathogenic fungi occur worldwide and can cause diseases in humans, animals and plants. Fungal infections in humans range from superficial, i.e., skin surface to deeply invasive type or disseminated infection. Some of such infections especially those that are disseminated are fatal. Thus fungal diseases can be divided into the life-threatening systemic infections, such as histoplasmosis, systemic candidiasis, aspergillosis, blastomycosis, coccidioidomycosis, paracoccidioidomycosis, and cryptococcosis, and more common ones which are non-life-threatening, like dermatophyte (ringworm) infections, including tinea pedis (athlete's foot), tinea cruris (jock itch), candidiasis, and actinomycosis.[0003]The life-threatening funga...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/00A61P37/04
CPCA61K2039/521A61K39/0002A61P37/04Y02A50/30
Inventor BOURINBAIAR, ALDAR S.JIRATHITIKAL, VICHAI
Owner IMMUNITOR USA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products